{"id":61116,"date":"2024-02-28T07:25:37","date_gmt":"2024-02-28T07:25:37","guid":{"rendered":"https:\/\/medsname.com\/champix\/"},"modified":"2026-05-01T10:49:16","modified_gmt":"2026-05-01T10:49:16","slug":"champix","status":"publish","type":"product","link":"https:\/\/medsbase.com\/nl\/champix\/","title":{"rendered":"Champix"},"content":{"rendered":"

<\/p>\n

\n

⚡ Quick Answer — Champix — varenicline 1 mg for smoking cessation<\/h3>\n

Champix is varenicline 1 mg, an α4β2 nicotinic-acetylcholine partial agonist that reduces nicotine cravings and the rewarding effect of smoking. Set a quit date 8–14 days into a 12-week course; titrate from 0.5 mg once daily up to 1 mg twice daily. Most effective when combined with behavioural support; the 2016 EAGLES trial removed the historical neuropsychiatric black-box.<\/p>\n<\/div>\n

\nWat u krijgt bij MedsBase:<\/strong> WHO-GMP gecertificeerde fabrikant \u00b7 Discrete verpakking \u00b7 Wereldwijde verzending \u00b7 1.400+ geverifieerde klantbeoordelingen<\/a>\n<\/div>\n

\ud83d\udce6 Elke bestelling is gedekt door onze Reshipment Assurance Policy<\/strong><\/a> \u2014 als uw pakket niet binnen 20 werkdagen arriveert, sturen wij het opnieuw.<\/p>\n

Waarom bestellen bij MedsBase<\/h3>\n

Onze generieke medicijnen zijn afkomstig van WHO-GMP gecertificeerde fabrikanten en worden wereldwijd verzonden in discrete, eenvoudige verpakkingen \u2014 geen medicijnnaam op de buitenkant van het pakket. Betalingen met kaart worden verwerkt via een gereguleerde processor (betalingsoverzichten vermelden een gereguleerde kaartbetalingprocessor \u2014 nooit \u201cMedsBase\u201d of een medicijnnaam). Crypto en SEPA bankoverschrijvingen worden ook geaccepteerd. Elke bestelling wordt ondersteund door ons Reshipment Assurance Policy.<\/p>\n

What is Champix?<\/h2>\n

Champix is a smoking-cessation aid containing varenicline 1 mg<\/strong> (film-coated tablets), supplied by Pfizer. It is a selective partial agonist at the α4β2 subtype of the neuronal nicotinic acetylcholine receptor — the same receptor nicotine binds — and is one of the most effective monotherapies for tobacco dependence, with cessation rates roughly two to three times those of placebo and consistently superior to single-agent nicotine-replacement therapy in head-to-head trials.<\/p>\n

How varenicline works<\/h2>\n

Varenicline binds the α4β2 nicotinic receptor with both agonist and antagonist<\/strong> properties: as a partial agonist it produces about 30–60% of nicotine’s dopamine release, dampening cravings and withdrawal; as an antagonist it occupies the receptor and blocks the dopaminergic surge from any cigarette smoked while on therapy, so a cigarette during the course feels much less rewarding than usual. This dual action distinguishes it from bupropion (an atypical antidepressant with weak nicotinic antagonism) and from nicotine-replacement therapy (full agonism only).<\/p>\n

How Champix is used<\/h2>\n

The standard adult course is 12 weken<\/strong>. Set a quit date 8–14 days into the course — do not stop smoking on day 1. An alternative “flexible quit” approach lets the smoker reduce gradually over the first 12 weeks and quit any time before the end.<\/p>\n\n\n\n\n\n\n\n\n
Days<\/th>\nDosering<\/th>\nOpmerkingen<\/th>\n<\/tr>\n<\/thead>\n
Dag 1\u20133<\/td>\n0.5 mg once daily<\/td>\nAfter breakfast<\/td>\n<\/tr>\n
Days 4–7<\/td>\n0.5 mg twice daily<\/td>\n12 hours apart<\/td>\n<\/tr>\n
Day 8 onwards (week 2–12)<\/td>\n1 mg twice daily<\/strong><\/td>\nMaintenance; quit date in this window<\/td>\n<\/tr>\n
Optional 12-week extension<\/td>\n1 mg twice daily<\/td>\nFor those who quit successfully — doubles 1-year abstinence rates<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Take with a full glass of water after a meal<\/strong> — nausea is the most common reason for discontinuation and is reduced by food and adequate hydration. If 1 mg twice daily is not tolerated, dropping back to 0.5 mg twice daily is acceptable and still active.<\/p>\n

Aanpassing van de nierdosis<\/h2>\n

Varenicline is excreted ~92% unchanged in urine. Dose adjustment is required in significant renal impairment:<\/p>\n\n\n\n\n\n\n\n
eGFR (mL\/min\/1.73 m\u00b2)<\/th>\nMaximale dosering<\/th>\n<\/tr>\n<\/thead>\n
≥ 30 (mild–moderate impairment)<\/td>\nStandard 1 mg BID<\/td>\n<\/tr>\n
< 30 (severe impairment)<\/td>\n1 mg once daily (titrate from 0.5 mg daily)<\/td>\n<\/tr>\n
Hemodialyse<\/td>\n0.5 mg once daily, may titrate to 1 mg once daily<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n
Neuropsychiatric history.<\/strong> The original FDA black-box warning (2009) was removed in 2016<\/strong> after the EAGLES trial (8,144 randomised smokers, including a stable-psychiatric cohort) found no statistically significant excess of clinically significant neuropsychiatric events versus placebo, NRT, or bupropion. However, smoking cessation itself can unmask underlying mood symptoms; patients with serious mental illness should still be monitored for new or worsening depression, anxiety, agitation, or suicidal ideation, especially in the first 4 weeks. Stop and contact a clinician if these emerge.<\/div>\n

Veelvoorkomende bijwerkingen<\/h2>\n